Cantor Fitzgerald Predicts Reduced Earnings for Belite Bio

Belite Bio, Inc (NASDAQ:BLTE) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Belite Bio in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per share of ($1.36) for the year, down from their prior estimate of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share.

Other analysts have also issued research reports about the company. Benchmark raised their target price on Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Belite Bio in a report on Tuesday.

Belite Bio Price Performance

Shares of BLTE opened at $67.28 on Thursday. The company has a market capitalization of $2.14 billion, a PE ratio of -60.61 and a beta of -1.54. Belite Bio has a one year low of $31.01 and a one year high of $86.53. The company’s fifty day moving average price is $59.48 and its 200 day moving average price is $60.84.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Institutional Trading of Belite Bio

A number of institutional investors and hedge funds have recently modified their holdings of BLTE. Advisors Preferred LLC bought a new position in Belite Bio in the fourth quarter worth $52,000. GAMMA Investing LLC lifted its holdings in shares of Belite Bio by 48.1% during the 4th quarter. GAMMA Investing LLC now owns 1,290 shares of the company’s stock worth $81,000 after acquiring an additional 419 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Belite Bio during the 4th quarter valued at about $155,000. XTX Topco Ltd bought a new stake in Belite Bio in the third quarter valued at about $253,000. Finally, JPMorgan Chase & Co. raised its position in Belite Bio by 7,122.7% in the third quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company’s stock worth $298,000 after purchasing an additional 6,268 shares in the last quarter. 0.53% of the stock is currently owned by institutional investors.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.